Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ESPERO: Eribulin +/- SB3 in HER2+ Breast Cancer
NCT05530057Phase 2Recruiting
- Sponsor
- Seoul National University Hospital
- Start
- Feb 2020
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in HER2-positive breast cancer (2 arms), sponsored by Seoul National University Hospital. Primary endpoint: Progression-Free Survival at 2 years. Started Feb 2020; status: recruiting.
02
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT05530057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05530057.